These findings suggest that combining MCT1 inhibitor AZD3965 with monoclonal antibodies against PD-L1 might be a promising therapeutic alternative to decrease tumor growth and restore the antitumor immune response. The gene discussed is SLC16A1; the disease is neoplasm.